Projected 2018 revenue for top 10 drugs approved U.S. 2013

Projected 2018 revenue for top 10 drugs approved in the U.S. in 2013 (in million U.S. dollars)

Projected 2018 revenue for top 10 drugs approved U.S. 2013 This statistic displays the projected 2018 revenue for top 10 drugs approved in the U.S. in 2013. Tivicay, approved on August 12, 2013, and developed by GlaxoSmithKline, is estimated to generate 2.13 billion U.S. dollars in annual revenue in 2018. Pharmaceutical and biotechnology companies experienced widespread growth worldwide with the United States garnering the largest growth.
Show more

Projected 2018 revenue for top 10 drugs approved in the U.S. in 2013 (in million U.S. dollars)

Loading statistic...
Product (approval date, company)Revenue in million U.S. dollars
Sovaldi (Dec 06, Gilead Sciences)5,221
Tecfidera (Mar 27, Biogen Idec)3,299
Kadcyla (Feb 22, Roche)3,049
Imbruvica (Nov 13, Pharmacyclics)2,453
Tivicay (Aug 12, GlaxoSmithKline)2,132
Breo Ellipta (May 10, GlaxoSmithKline)1,332
Anoro Ellipta (Dec 18, GlaxoSmithKline)1,242
Gazyva (Nov 01, Roche)1,149
Brintellix (Sep 30, Takeda)875
Xofigo (May 15, Bayer)829
Product (approval date, company)Revenue in million U.S. dollars
Sovaldi (Dec 06, Gilead Sciences)5,221
Tecfidera (Mar 27, Biogen Idec)3,299
Kadcyla (Feb 22, Roche)3,049
Imbruvica (Nov 13, Pharmacyclics)2,453
Tivicay (Aug 12, GlaxoSmithKline)2,132
Breo Ellipta (May 10, GlaxoSmithKline)1,332
Anoro Ellipta (Dec 18, GlaxoSmithKline)1,242
Gazyva (Nov 01, Roche)1,149
Brintellix (Sep 30, Takeda)875
Xofigo (May 15, Bayer)829
Download Settings Share
Download started
Please be patient - this may take a moment
This statistic displays the projected 2018 revenue for top 10 drugs approved in the U.S. in 2013. Tivicay, approved on August 12, 2013, and developed by GlaxoSmithKline, is estimated to generate 2.13 billion U.S. dollars in annual revenue in 2018. Pharmaceutical and biotechnology companies experienced widespread growth worldwide with the United States garnering the largest growth.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Pharmaceutical industry in Norway "
  • Overview
The most important statistics
  • Production and trade
  • Pharmaceutical turnover
  • R&D, patents and new products
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.